Shares of Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) hit a new 52-week low during trading on Monday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 45000 shares trading hands. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Stock Performance
The company has a debt-to-equity ratio of 138.88, a current ratio of 0.07 and a quick ratio of 0.46. The company has a fifty day moving average price of C$0.01 and a two-hundred day moving average price of C$0.02. The company has a market capitalization of C$663,150.00, a P/E ratio of -0.50 and a beta of -0.02.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
See Also
- Five stocks we like better than Aequus Pharmaceuticals
- Market Cap Calculator: How to Calculate Market Cap
- Dow Jones: A Relevant Benchmark or a Relic of the Past?
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- What Are Treasury Bonds?
- Market Overreaction: 2 Stocks to Buy on the Way Down
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
